Research
Hormonal
Thiazolidinediones (TZDs) increase circulating adiponectin levels, particularly the high molecular weight (HMW) form, by stimulating transcription and preventing ER retention.
This node describes a prescription medication class (TZDs) that increases adiponectin. This is not a self-administered intervention but a medical treatment for diabetes. Consult a physician for prescription options.
GoodSupportsHIGH confidence
The Thiazolidinedione class of medications (TZDs) are PPARγ agonists that stimulate adiponectin production... Similarly, ERp44 inhibition using TZDs may be utilized to prevent ER retention of adiponectin and increase its circulatory levels.
Why this rating
Supported by multiple in vitro and in vivo studies cited in the review.
Source
Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease
Sheetal Parida et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20102519
narrative_reviewCited 242×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity causes a significant reduction in circulating adiponectin levels, which contributes to insulin resistance, metabolic syndrome, and increased cancer risk.Good
- Low levels of adiponectin are associated with an increased risk of various cancers, including breast, liver, pancreatic, prostate, ovarian, and colorectal cancers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →